Development of biosimilars in an era of oncologic drug shortages
about
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published EvidenceRituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.Biosimilars for the Treatment of Cancer: A Systematic Review of Published EvidenceTime spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory studyA phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients.Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.Economics of ramucirumab for metastatic colorectal cancer.Drug tendering: drug supply and shortage implications for the uptake of biosimilarsBiosimilars: Key regulatory considerations and similarity assessment tools.Improving Access to Cancer Treatments: The Role of Biosimilars.The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.Derivatives (halogen, nitro and amino) of 8-hydroxyquinoline with highly potent antimicrobial and antioxidant activities.The process defines the product: what really matters in biosimilar design and production?Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin AmericaQuality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections
P2860
Q28078423-1CF11448-6FD4-4DDA-8DE5-2C28211673D7Q33621041-E41131B2-6F01-4B96-873F-8621211D0AF4Q36247037-FA4BA1A7-6143-4289-BF03-096B835876C4Q36325432-46B88E2B-9655-47A2-AF7A-F2E545C17C2DQ36396272-89E75B3E-7DFE-45D5-97DB-6FF41D3D383FQ38643555-C07308D3-63B3-4505-9785-A8729F348014Q39003764-9006F2C1-6ACF-4D9D-AFC8-40052B2D1F28Q42370596-0E521913-FEF3-4870-9021-4E5A7D18DE5CQ46729332-D63B5763-4FDC-44F1-8134-286EE6ABA2E9Q47099597-E72C9C92-D93A-4AE2-A5C5-F241A822A2B4Q47796704-7D97451E-D426-40CF-AFFB-B33D8E9BC7AFQ48307011-DF35BD39-04DC-4EEE-BC65-EF404568D8F4Q49195155-F2FF7DC7-DBA1-4621-A4BB-C7A08CFE5A4AQ50115805-D5DEC822-3A5A-4D79-8008-4F3FD3DE24AAQ57173064-1B9B9D26-DD54-4499-99A3-0D72F804FB7AQ58796183-42D69B16-1346-47A0-B3D8-51E3CA67DC51
P2860
Development of biosimilars in an era of oncologic drug shortages
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Development of biosimilars in an era of oncologic drug shortages
@ast
Development of biosimilars in an era of oncologic drug shortages
@en
Development of biosimilars in an era of oncologic drug shortages
@nl
type
label
Development of biosimilars in an era of oncologic drug shortages
@ast
Development of biosimilars in an era of oncologic drug shortages
@en
Development of biosimilars in an era of oncologic drug shortages
@nl
prefLabel
Development of biosimilars in an era of oncologic drug shortages
@ast
Development of biosimilars in an era of oncologic drug shortages
@en
Development of biosimilars in an era of oncologic drug shortages
@nl
P2093
P2860
P356
P1476
Development of biosimilars in an era of oncologic drug shortages
@en
P2093
Dolca Thomas
Ira Jacobs
Janakiraman Subramanian
Jason McKinley
Scott Anderson
P2860
P304
P356
10.2147/DDDT.S75219
P407
P5008
P577
2015-06-24T00:00:00Z